These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1037443)

  • 21. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms].
    Lucchelli PD; Monarca A; Del Mastro S; Sega R
    Boll Chim Farm; 1978 Aug; 117(8):487-95. PubMed ID: 743391
    [No Abstract]   [Full Text] [Related]  

  • 23. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of endocrine systemic side effects after topical application of spironolactone in man.
    Rey FO; Valterio C; Locatelli L; Ramelet AA; Felber JP
    J Endocrinol Invest; 1988 Apr; 11(4):273-8. PubMed ID: 3411088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Species differences in the metabolism and disposition of spironolactone.
    Karim A; Kook C; Zitzewitz DJ; Zagarella J; Doherty M; Campion J
    Drug Metab Dispos; 1976; 4(6):547-55. PubMed ID: 11976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
    Langguth P; Hanafy A; Frenzel D; Grenier P; Nhamias A; Ohlig T; Vergnault G; Spahn-Langguth H
    Drug Dev Ind Pharm; 2005 Mar; 31(3):319-29. PubMed ID: 15830727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bioavailability of spironolactone hydrochlorothiazide combination preparation.
    Rameis H; Hitzenberger G; Horwatitsch H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jul; 20(7):327-33. PubMed ID: 7107086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats.
    Kaukonen AM; Lennernäs H; Mannermaa JP
    J Pharm Pharmacol; 1998 Jun; 50(6):611-9. PubMed ID: 9680070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].
    d'Athis P; Richard MO; de Lauture D; Rey E; Bouvier d'Yvoire M; Clement E; Olive G
    Therapie; 1981; 36(4):443-9. PubMed ID: 7292427
    [No Abstract]   [Full Text] [Related]  

  • 31. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 32. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 33. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relative bioavailability of a new spironolactone preparation (author's transl)].
    Erking W; Lücker PW; Stöcker KP; Wetzelsberger K
    Arzneimittelforschung; 1979; 29(8):1184-9. PubMed ID: 583021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 40. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.